433 Participants Needed

Immune Therapy + Bevacizumab for Advanced Liver Cancer

Recruiting at 38 trial locations
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise

Trial Summary

What is the purpose of this trial?

This is a multicenter, open-label, stratified, randomized study to evaluate the safety, tolerability, antitumor activity, pharmacokinetics, pharmacodynamics, and immunogenicity of durvalumab or tremelimumab monotherapy, or durvalumab in combination with tremelimumab or bevacizumab in advanced hepatocellular carcinoma.

Research Team

ML

MedImmune, LLC MedImmune, LLC

Principal Investigator

MedImmune LLC

Eligibility Criteria

This trial is for adults with advanced liver cancer who have either not responded to, cannot tolerate, or chose not to use sorafenib or similar drugs. It's also open to those who haven't had any systemic therapy for their cancer. People can't join if they've had certain complications like ascites needing intervention, hepatic encephalopathy, major blood vessel thrombosis in the liver, active autoimmune diseases, recent immunosuppressive meds use, or gastrointestinal bleeding within the last year.

Inclusion Criteria

I have liver cancer and cannot tolerate or have refused standard treatments.
I am at least 18 years old (20 if in Japan).
I have never received immunotherapy.
See 2 more

Exclusion Criteria

I've needed a procedure to remove excess belly fluid in the last 6 months.
I am not currently on any cancer treatments like chemotherapy or immunotherapy.
I haven't taken immunosuppressive drugs in the last 14 days, with some exceptions.
See 5 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive various dosing regimens of durvalumab, tremelimumab, and bevacizumab based on the study part and cohort

Until confirmed progressive disease or other discontinuation criteria

Follow-up

Participants are monitored for safety and effectiveness after treatment

12 months after the first dose of study drug given to the last participant

Survival Follow-up

All participants will be followed for survival until the end of study visit

Until the last participant discontinues the study treatment

Treatment Details

Interventions

  • Bevacizumab
  • Durvalumab
  • Tremelimumab
Trial Overview The study is testing different treatments: Durvalumab alone; Tremelimumab alone; and combinations of Durvalumab with Tremelimumab or Bevacizumab. The goal is to see how safe these treatments are and how well they work against advanced liver cancer by monitoring tumor response and changes in the body's immune system.
Participant Groups
9Treatment groups
Experimental Treatment
Group I: Parts 2 and 3: Tremelimumab 750 mgExperimental Treatment1 Intervention
Participants will receive tremelimumab 750 mg Q4W 7 doses followed by every 12 weeks (Q12W) until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.
Group II: Parts 2 and 3: Tremelimumab 75 mg + Durvalumab 1500 mgExperimental Treatment2 Interventions
Participants will receive tremelimumab 75 mg Q4W 4 doses and durvalumab 1500 mg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first. Participant recruitment to this arm was closed following protocol amendment 5.
Group III: Parts 2 and 3: Tremelimumab 300 mg + Durvalumab 1500 mgExperimental Treatment2 Interventions
Participants will receive tremelimumab 300 mg 1 dose and durvalumab 1500 mg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow, or development of other reason for treatment discontinuation, whichever occurs first.
Group IV: Parts 2 and 3: Durvalumab 1500 mgExperimental Treatment1 Intervention
Participants will receive durvalumab 1500 mg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.
Group V: Part 4: Durvalumab 1120 mg + Bevacizumab 15 mg/kgExperimental Treatment2 Interventions
Participants will receive durvalumab 1120 mg and bevacizumab 15 mg/kg every 3 weeks (Q3W) until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first
Group VI: Part 1: Tremelimumab 1 mg/kg + Durvalumab 20 mg/kgExperimental Treatment2 Interventions
Participants in Part 1A (safety run-in cohort) and Part 1 B (efficacy-gating cohort) will receive tremelimumab 1 mg/kg every 4 weeks (Q4W) 4 doses and durvalumab 20 mg/kg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.
Group VII: China Cohort: Tremelimumab 10 mg/kgExperimental Treatment1 Intervention
Participants will receive tremelimumab 10 mg/kg Q4W 7 doses followed by Q12W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.
Group VIII: China Cohort: Tremelimumab 1 mg/kg + Durvalumab 20 mg/kgExperimental Treatment2 Interventions
Participants will receive tremelimumab 1 mg/kg Q4W 4 doses and durvalumab 20 mg/kg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.
Group IX: China Cohort: Durvalumab 20 mg/kgExperimental Treatment1 Intervention
Participants will receive durvalumab 20 mg/kg Q4W until confirmed progressive disease, withdrawal of consent, lost to follow-up, or development of other reason for treatment discontinuation, whichever occurs first.

Durvalumab is already approved in European Union, United States, Japan for the following indications:

🇪🇺
Approved in European Union as Imfinzi for:
  • Locally advanced, unresectable non-small cell lung cancer (NSCLC)
🇺🇸
Approved in United States as Imfinzi for:
  • Extensive-stage small cell lung cancer (ES-SCLC)
  • Limited-stage small cell lung cancer (LS-SCLC)
  • Locally advanced or metastatic urothelial carcinoma
🇯🇵
Approved in Japan as Imfinzi for:
  • Not specified in provided sources

Find a Clinic Near You

Who Is Running the Clinical Trial?

MedImmune LLC

Lead Sponsor

Trials
348
Recruited
788,000+
Founded
1988
Headquarters
Gaithersburg, USA
Known For
Biologics research
Top Products
Synagis, FluMist
Dr. Reginald Seeto profile image

Dr. Reginald Seeto

MedImmune LLC

Chief Medical Officer since 2008

MD from University of Sydney, B.Sc. from University of Sydney

Peter Greenleaf profile image

Peter Greenleaf

MedImmune LLC

Chief Executive Officer since 2006

MBA from St. Joseph’s University, B.S. from Western Connecticut State University

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security